Skip to content

A Clinical study on Amal Tablets in constipation

A Clinical study to evaluate efficacy and safety of Amal Tablets in the Management of Functional Constipation and Irregular Bowel Habit-An Open Label, Randomized, Comparative, Multi centric, Interventional, Prospective, Clinical Study - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055837
Enrollment
60
Registered
2023-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K590- Constipation

Interventions

None listed

Sponsors

SANDOOK SUTRAS PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects presenting with two or more of the following for the last 3 months with symptom onset at least 6 months prior to diagnosis a) Straining during more than one fourth (25 percentage) of defecations b) Lumpy or hard stools (Bristol Stool Form Scale 1to 2) more than one fourth (25 percentage) of defecations c) Sensation of incomplete evacuation more than one fourth (25 percentage) of defecations d) Sensation of anorectal obstruction/blockage more than one fourth (25 percentage) of defecations e) Manual manoeuvres to facilitate more than one fourth (25 percentage) of defecations (e.g., digital evacuation, support of the pelvic floor) f) Fewer than three SBM per week g) Loose stools are rarely present without the use of laxatives h) Insufficient criteria for irritable bowel syndrome 3. Subjects who are ready to provide written informed consent and who are ready to willingly participate and follow the protocol requirements of the clinical study. (The Rome 4 diagnostic criteria for Functional constipation, 2016)

Exclusion criteria

Exclusion criteria: 1. Subjects diagnosed with colonic inertia. 2. Subjects who have recently undergone abdominal surgery 3. Subjects with history of anorectal surgery. 4.Subjects having other functional gastrointestinal disorders other than Functional constipation (IBS, Belching disorders etc.) 5. Subjects diagnosed with structural abnormalities, like: a). Anorectal: rectal prolapse, rectocele, rectal intussusceptions, anorectal stricture, solitary rectal ulcer syndrome b). Perineal descent c). Colonic or rectal mass or tumor with obstruction example adenocarcinoma d). Colonic stricture: radiation, ischemia, diverticulosis e). Intestinal obstruction. 6. Subjects with uncontrolled DM and hypertension and Tuberculosis. 7. Known cases of HIV, tuberculosis, hypo and hyperthyroidism 8. Known cases of renal or liver dysfunction. 9. Subjects diagnosed with neurological problems like, a). Parkinson’s disease b). Multiple sclerosis c). Sacral nerve damage (prior pelvic surgery, tumor) d). Paraplegia e). Autonomic neuropathy 10. Subjects on chronic medication (greater than 60 days) and or who are on medications known to cause constipation. 11. Pregnant or lactating females 12. Subjects allergic or atopic to any of the ingredients of the study medications 13. Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol.

Design outcomes

Primary

MeasureTime frame
Change in frequency of bowel movementsTimepoint: Screening visit (Up to 3 days), Baseline visit (Day 0), Visit 1 (Day 7), Visit 2 (Day 14), Visit 3 (Day 21)

Secondary

MeasureTime frame
1. Change in stool form on ‘Bristol stool form scale’ 2. Changes in symptoms of functional constipation including 3. Changes in associated clinical symptoms 4. Average time required for the subject to evacuate bowel after consumption of study medicine 5. Global assessment of overall change 6. Assessment of tolerability of study products 7. Assessment of laboratory investigationsTimepoint: Screening visit (Up to 3 days), Baseline visit (Day 0), Visit 1 (Day 7), Visit 2 (Day 14), Visit 3 (Day 21)

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research Pvt. Ltd

targetinstitute@yahoo.com09322522252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026